

product was first quantified on an initial gel. The proportion of maternal or paternal alleles in each lane was then determined from a second gel after cutting the PCR product. These values were obtained by scanning the autoradiographs.

Received 13 June; accepted 17 September 2001.

1. Pernis, B., Chiappino, G., Kelus, A. S. & Gell, P. G. Cellular localization of immunoglobulins with different allotypic specificities in rabbit lymphoid tissues. *J. Exp. Med.* **122**, 853–876 (1965).
2. Cebra, J. J., Colberg, J. E. & Dray, S. Rabbit lymphoid cells differentiated with respect to alpha-, gamma-, and mu-heavy polypeptide chains and to allotypic markers Aa1 and Aa2. *J. Exp. Med.* **123**, 547–558 (1966).
3. Rajewsky, K. Clonal selection and learning in the antibody system. *Nature* **381**, 751–758 (1996).
4. Mostoslavsky, R. *et al.* κ chain monoallelic demethylation and the establishment of allelic exclusion. *Genes Dev.* **12**, 1801–1811 (1998).
5. Simon, I. & Cedar, H. in *DNA Replication in Eukaryotic Cells* (ed. DePamphilis, M. L.) 387–408 (Cold Spring Harbor Laboratory Press, New York, 1996).
6. Selig, S., Okumura, K., Ward, D. C. & Cedar, H. Delineation of DNA replication time zones by fluorescence in situ hybridization. *EMBO J.* **11**, 1217–1225 (1992).
7. Kitsberg, D. *et al.* Allele-specific replication timing of imprinted gene regions. *Nature* **364**, 459–463 (1993).
8. Chess, A., Simon, I., Cedar, H. & Axel, R. Allelic inactivation regulates olfactory receptor gene expression. *Cell* **78**, 823–834 (1994).
9. Takagi, N. Differentiation of X chromosomes in early female mouse embryos. *Exp. Cell Res.* **86**, 127–135 (1974).
10. Cedar, H. & Bergman, Y. Developmental regulation of immune system gene rearrangement. *Curr. Opin. Immunol.* **11**, 64–80 (1999).
11. Takeda, S. *et al.* Deletion of the immunoglobulin κ chain intron enhancer abolishes κ chain gene rearrangement in *cis* but not λ chain gene rearrangement in *trans*. *EMBO J.* **12**, 2329–2336 (1993).
12. Gorman, J. R. *et al.* The Ig κ 3' enhancer influences the ratio of Ig κ versus Ig λ B lymphocytes. *Immunology* **5**, 241–252 (1996).
13. Apel, T. W. *et al.* The ribose 5-phosphate isomerase-encoding gene is located immediately downstream from that encoding murine immunoglobulin kappa. *Gene* **156**, 191–197 (1995).
14. Simon, I. *et al.* Asynchronous replication of imprinted genes is established in the gametes and maintained during development. *Nature* **401**, 929–932 (1999).
15. Betz, A. G. *et al.* Elements regulating somatic hypermutation of an immunoglobulin kappa gene: critical role for the intron enhancer/matrix attachment region. *Cell* **77**, 239–248 (1994).
16. Casellas, R. *et al.* Contribution of receptor editing to the antibody repertoire. *Science* **291**, 1541–1544 (2001).
17. Soriano, P. Generalized *lacZ* expression with the ROSA26 Cre reporter strain. *Nature Genet.* **21**, 70–71 (1999).
18. Tenzen, T. *et al.* Precise switching of DNA replication timing in the GC content transition area in the human major histocompatibility complex. *Mol. Cell Biol.* **17**, 4043–4050 (1997).
19. Luning-Prak, E. & Weiger, M. Light chain replacement: a new model for antibody gene rearrangement. *J. Exp. Med.* **182**, 541–548 (1995).
20. Jolly, C. & Neuberger, M. Somatic hypermutation of immunoglobulin kappa transgenes: Association of mutability with demethylation. *Immunol. Cell Biol.* **79**, 18–22 (2001).
21. Mullins, L. J., Veres, G., Caskey, C. T. & Chapman, V. Differential methylation of the ornithine carbamoyl transferase gene on active and inactive mouse X chromosomes. *Mol. Cell Biol.* **7**, 3916–3922 (1987).
22. Nadon, N., Korn, N. & DeMars, R. A-11: cell type-specific and single-active-X transcription controls of newly found gene in cultured human cells. *Somat. Cell Mol. Genet.* **14**, 541–552 (1988).
23. Eggan, K. *et al.* X-Chromosome inactivation in cloned mouse embryos. *Science* **290**, 1578–1581 (2000).
24. Chess, A. Expansion of the allelic exclusion principle? *Science* **279**, 2067–2068 (1998).
25. Hogan, B., Beddington, R., Constantini, F. & Lacey, E. *Manipulating the Mouse Embryo. A Laboratory Manual* (Cold Spring Harbor Laboratory Press, New York, 1994).
26. McCarrey, J. R., Hsu, K. C., Eddy, E. M., Klevecz, R. R. & Bolen, J. L. Isolation of viable mouse primordial germ cells by antibody-directed flow sorting. *J. Exp. Zool.* **242**, 107–111 (1987).
27. Belle, A. R. *et al.* Spermatogenic cells of the prepubertal mouse, isolation and morphological characterization. *J. Cell Biol.* **74**, 68–85 (1977).
28. Rolink, A., Kudo, A., Karasuyama, H., Kikuchi, Y. & Melchers, F. Long-term proliferating early pre-B cell lines and clones with the potential to develop to surface Ig-positive, mitogen reactive B cells in vitro and in vivo. *EMBO J.* **10**, 327–336 (1991).
29. Spanopoulou, E. *et al.* Functional immunoglobulin transgenes guide ordered B-cell differentiation in Rag-1-deficient mice. *Genes Dev.* **8**, 1030–1042 (1994).
30. Jat, P. S., Cepko, C. L., Mulligan, R. C. & Sharp, P. A. Recombinant retroviruses encoding simian virus 40 large T antigen and polyomavirus large and middle T antigens. *Mol. Cell Biol.* **6**, 1204–1217 (1986).
31. Skok, J. A. *et al.* Nonequivalent nuclear location of immunoglobulin alleles in B lymphocytes. *Nature Immunol.* **2**, 848–854 (2001).
32. Gorman, J. R. & Alt, F. Regulation of immunoglobulin light chain isotype expression. *Adv. Immunol.* **69**, 113–181 (1998).

Acknowledgements

We thank K. Rajewsky, F. Alt and P. Soriano for kindly providing the iE κ T^{-/-}, 3'E κ T^{-/-} and ROSA26 reporter mice; B. Van Ness, F. Sablitzky, H. Schroeder, J. Roes, J. Chen, L. Jackson-Grusby, D. Ward, P. Fraser, N. Benvenisti, D. Littman, F. Alt, M. Reth, H. Zachau and I. Simon for FISH probes; B. Tuberli for help with early embryo manipulations; Z. Werb for the antibody used to purify ICM; G. Paridis, F. Ebrahimi and J. Gribnau for advice regarding cell lines and FISH; I. Simon for discussions. This work was supported by grants from the Israel Academy of sciences (Y.B. and H.C.), German Israel Foundation (Y.B.), the NIH (A.C., Y.B. and H.C.), European Community 5th Framework Quality of Life Program (Y.B.) and the Israel Cancer Research Fund (H.C.). A.C. is a Rita Allen Foundation Scholar.

Correspondence and requests for materials should be addressed to H.C. (e-mail: cedar@md2.huji.ac.il) and A.C. (e-mail: chess@wi.mit.edu).

.....
Identification of the cellular receptor for anthrax toxin

Kenneth A. Bradley*^{†‡}, Jeremy Mogridge*^{‡§}, Michael Mourez[§], R. John Collier[§] & John A. T. Young*

* *McArdle Laboratory for Cancer Research, University of Wisconsin—Madison, 1400 University Avenue, Madison, Wisconsin 53706, USA*

[†] *Biological and Biomedical Sciences Graduate Program, and* [§] *Department of Microbiology and Molecular Genetics, Harvard Medical School, 200 Longwood Avenue, Boston, Massachusetts 02115, USA*

[‡] *These authors contributed equally to the work*

The tripartite toxin secreted by *Bacillus anthracis*, the causative agent of anthrax, helps the bacterium evade the immune system and can kill the host during a systemic infection. Two components of the toxin enzymatically modify substrates within the cytosol of mammalian cells: oedema factor (OF) is an adenylate cyclase that impairs host defences through a variety of mechanisms including inhibiting phagocytosis^{1,2}; lethal factor (LF) is a zinc-dependent protease that cleaves mitogen-activated protein kinase kinase and causes lysis of macrophages^{3–5}. Protective antigen (PA), the third component, binds to a cellular receptor and mediates delivery of the enzymatic components to the cytosol. Here we describe the cloning of the human PA receptor using a genetic complementation approach. The receptor, termed ATR (anthrax toxin receptor), is a type I membrane protein with an extracellular von Willebrand factor A domain that binds directly to PA. In addition, a soluble version of this domain can protect cells from the action of the toxin.

After binding to the cell-surface receptor, PA is cleaved into two fragments by a furin-like protease⁶. The amino-terminal fragment, PA₂₀, dissociates into the medium, and this allows the carboxy-terminal fragment, PA₆₃, to heptamerize and to bind LF and OF^{7,8}. The resulting complexes of [PA₆₃]₇ with OF and/or LF are taken up into cells by receptor-mediated endocytosis and moved to a low-pH endosomal compartment⁹. There, the acidic environment induces a conformational change in [PA₆₃]₇ that allows it to insert into the membrane and form a pore^{10–12}. This conversion promotes the translocation of bound OF and LF across the endosomal membrane to the cytosol.

Previous studies have indicated that the receptor to which PA binds is a ubiquitous protein expressed at moderately high levels on cell surfaces (for example, 10⁴ and 3 × 10⁴ receptors per cell on CHO-K1 cells and macrophage cell lines, respectively)^{13,14}. To identify this receptor, we first generated a mutant cell line lacking receptor, so that the defect could be genetically complemented. ICR-191, a DNA alkylating agent that induces small deletions and frameshift mutations in genes¹⁵, was used to introduce random mutations in the hypodiploid CHO-K1 cell line under conditions that led to about 90% cell death. The surviving mutagenized cells were then challenged with PA and LF_N-DTA, a fusion protein composed of the N-terminal 255 amino acids of LF linked to the catalytic A chain of diphtheria toxin¹⁶. This recombinant toxin can kill CHO-K1 cells (in contrast to LF and PA) and it exploits the same LF-PA-receptor interactions that are required for the binding and entry of the native LF and OF proteins. Ten single-cell colonies (designated as CHO-R1.1 to CHO-R1.10) that survived toxin treatment were isolated. In control experiments performed with non-mutagenized CHO-K1 cells, no toxin-resistant cell clones were detected. One of the mutagenized clones (CHO-R1.1) was chosen for further analysis.

|| Present address: Department of Laboratory Medicine and Pathobiology, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada.




Figure 1 Mutant CHO-R1.1 cells display a decreased OGPA-binding phenotype that can be corrected by overexpression of the ATR cDNA. **a**, Mutant CHO-R1.1 and wild-type CHO-K1 cells were incubated with 40 nM OGPA for 2 h on ice, washed twice then analysed by flow cytometry. **b**, Mutant and wild-type CHO cells were transduced with an MLV vector encoding ATR and then stained with OGPA as above. **c**, Expression of ATR restores toxin sensitivity. CHO-R1.1 cells (filled circles), CHO-K1 cells (filled squares) and

CHO-R1.1 and CHO-K1 cells transduced with the MLV vector encoding ATR (open circles and squares, respectively) were treated with 10⁻⁹ M LF_n-DTA and various concentrations of PA. About 70% of the transduced CHO-R1 cells expressed ATR as judged by OGPA staining. Medium containing 1 μCi ml⁻¹ ³H-leucine was then added to cells for 1 h, and the amount of ³H-leucine incorporated into cellular proteins was determined by precipitation with trichloroacetic acid and liquid scintillation counting¹⁶.




Figure 2 Sequence alignment of ATR with the I domain of integrin α2 (α2-I), the von Willebrand factor A domain consensus sequence (WVA-CON, generated from 210 sequences aligned by the National Center for Biotechnology Information), and TEM8. The secondary structural elements are based on the crystal structure of the α2-I domain³⁰. Conserved amino acids are boxed and identical amino acids are indicated by shaded

boxes. The putative signal sequence is underlined. The five residues that form the MIDAS motif are indicated with asterisks. The putative transmembrane domains of ATR and TEM8 are indicated by a shaded box. Potential N-linked glycosylation sites in ATR and TEM8 are indicated by hatched boxes. The alignment was made with the programs ClustalW and ESPript 1.9 (the Risler matrix was used with a global score of 0.7).

CHO-R1.1 cells were fully susceptible to killing by diphtheria toxin (data not shown), thus ruling out the possibility that resistance to PA with LF_N-DTA was due to a defect in the pathway of DT action. To test directly whether CHO-R1.1 cells lacked the receptor, we performed flow cytometric analysis using an Oregon Green-conjugated form of PA (OGPA). CHO-R1.1 cells were significantly impaired in their ability to bind to OGPA compared with the parental cell line (Fig. 1a), suggesting that these mutagenized cells had lost expression of the putative PA receptor gene. Similar analysis of the other nine mutant CHO-R1 clones demonstrated that they were also defective in binding to OGPA (data not shown).

In an attempt to complement the PA-binding defect of CHO-R1.1 cells, the cells were transduced with a retrovirus-based complementary DNA library (Clontech) prepared from human HeLa cells that express the PA receptor (J.M., unpublished data). This cDNA library is contained in a murine leukemia virus (MLV) vector that is packaged into pseudotyped virus particles (MLV[VSV-G]) containing the broad host-range G protein of vesicular stomatitis virus (VSV-G)¹⁷. Retrovirus-based cDNA libraries are useful for genetic complementation approaches because they can be used to deliver a limited number of stably expressed cDNA molecules per cell. These molecules can be rapidly re-isolated by polymerase chain reaction (PCR) amplification using MLV vector-specific oligonucleotide primers^{18,19}.

The transduced CHO-R1.1 cells were subjected to five rounds of flow cytometric sorting to isolate those that contained the cDNA clone of the putative PA receptor. Cells were sorted on the basis of their binding of OGPA in combination with an anti-PA polyclonal serum and an allophycocyanin (APC) conjugated secondary antibody. This led to the isolation of a cell population in which greater than 90% of the cells bound OGPA. This complemented cell population contained at least seven unique cDNA inserts that were obtained by the PCR amplification method described above. Each cDNA was gel purified, subcloned back into the parent pLIB vector and packaged into MLV(VSV-G) virions so that it could be tested for its ability to complement the PA-binding defect of CHO-R1.1 cells. One cDNA clone of about 1.5 kilobases (kb) (designated

as *ATR*) restored PA binding to CHO-R1.1 cells (Fig. 1b). This clone also markedly enhanced the binding of PA to parental CHO-K1 cells (Fig. 1b). Furthermore, the *ATR* cDNA clone fully restored the sensitivity of CHO-R1.1 cells to the toxin LF_N-DTA with PA (Fig. 1c).

Sequencing of the *ATR* cDNA clone revealed a single long open reading frame, encoding a 368-amino-acid protein. The protein is predicted to have a signal peptide 27 amino acids long, an extracellular domain 293 amino acids long with three putative N-linked glycosylation sites, a putative transmembrane region 23 amino acids long, and a short cytoplasmic tail (Fig. 2). A BLAST search revealed that the first 364 amino acids of *ATR* are identical to a protein encoded by the human *TEM8* cDNA clone (GenBank accession number NM032208). *TEM8* is upregulated in colorectal cancer endothelium, but the function of this protein has not been reported²⁰. The C-terminal ends of *ATR* and the *TEM8* protein then diverge, presumably as a consequence of alternative splicing, such that *ATR* has a cytoplasmic tail of only 25 amino acids whereas *TEM8* is predicted to have a cytoplasmic tail 221 amino acids long (Fig. 2).

The most notable feature of *ATR* is the presence of an extracellular von Willebrand factor type A (VWA) domain, located between residues 44 and 216 (Fig. 2). VWA domains are present in the extracellular regions of a variety of cell surface proteins, including matrilins and integrins (designated as I domains). These domains are important for protein-protein interactions and constitute ligand-binding sites for integrins²¹. Ligand binding through I domains requires an intact MIDAS (metal ion-dependent adhesion site) motif²², which seems to be conserved in *ATR* (Fig. 2). The cytoplasmic tail of *ATR* contains an acidic cluster (AC motif; EESEE) that is similar to a motif found in the cytoplasmic tail of furin that specifies basolateral sorting of this protease in polarized epithelial cells²³. This may be significant because the PA receptor localizes to the basolateral surface of polarized epithelial cells²⁴ and we expect that the receptor and the protease needed to bind and activate PA would be colocalized to allow for efficient entry of anthrax toxins.




Figure 3 The VWA/I domain of *ATR* binds directly to PA. **a**, Wild-type PA (WT) or a receptor-binding mutant of PA (N682S) were mixed with T7-*ATR*₄₁₋₂₂₇ on ice for 30 min in the presence or absence of 2 mM EDTA, as indicated. A polyclonal serum specific for PA and protein A sepharose were then added, the PA-associated proteins were precipitated, subjected to SDS-PAGE, transferred to nitrocellulose, and probed with anti-T7 antibody conjugated to horseradish peroxidase. **b**, GST or GST-D4 (GST fused to domain 4 of PA) coupled to glutathione sepharose (Pharmacia) was incubated with T7-*ATR*₄₁₋₂₂₇ for 1 h at 4 °C and the samples were precipitated and analysed as described

above. **c**, CHO-K1 cells were incubated with LF_N-DTA (10⁻⁹ M) and various concentrations of wild-type PA (filled circles) or PA-N682S mutant (open circles) and cell viability was determined as in Fig. 1c. **d**, CHO-K1 cells were incubated with 2 × 10⁻⁸ M trypsin-nicked PA (wild type or N682S) for 1 h. Cells were washed with PBS, resuspended in SDS sample buffer and run on a 4–20% SDS-PAGE gel. PA was visualized by western blotting. Lane 1 (**a,b**), T7-*ATR*₄₁₋₂₂₇ loading control; lane 2 (**a**) and lane 1 (**d**) anti-PA serum control (no PA added).

Given the likelihood that ATR is conserved among different species, it is of interest to note that the product of the mouse homologue of ATR/TEM8 (GenBank accession number AK013005) is highly related to the human clones, sharing greater than 98% sequence identity within the reported extracellular domain (data not shown). Furthermore, consistent with the observation that the anthrax toxin receptor is found in a variety of cell lines, ATR and/or TEM8 is expressed in a number of different tissues including the central nervous system, heart, lung and lymphocytes (data not shown; and see NCBI UniGene cluster Hs.8966 at <http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Hs&CID=8966&OPT=text>).

To confirm that PA binds directly to ATR, co-immunoprecipitations were performed with an extracellular fragment of ATR and either the wild-type or a mutant form of PA deficient in receptor binding. A fusion protein consisting of a hexahistidine tag, a T7 tag, and amino acids 41–227 of ATR (the I domain) was expressed and purified from *Escherichia coli* cells. When mixed with wild-type PA, this construct, T7-ATR_{41–227}, was precipitated with polyclonal anti-PA serum (Fig. 3a, lane 3). The interaction between PA and T7-ATR_{41–227} was impaired by the presence of EDTA (Fig. 3a, lane 5), demonstrating that the interaction requires divalent cations and suggesting that the MIDAS motif of ATR is critical for binding PA. In addition, a fusion protein consisting of glutathione S-transferase (GST) and the receptor-binding domain 4 (D4)^{25,26} of PA (GST-D4) bound T7-ATR_{41–227}, whereas GST did not (Fig. 3b). PA-N682S, a mutant form of PA with residue Asn 682 replaced with Ser, is impaired in its ability to bind and intoxicate cells (Fig. 3c and d), and was unable to bind to T7-ATR_{41–227} (Fig. 3a, lane 4). These experiments demonstrate a direct and specific interaction between the VWA/I domain of ATR and the receptor-binding domain of PA.

Given this direct interaction, we reasoned that ATR_{41–227} might protect CHO-K1 cells from being killed by PA and LF_N-DTA. We tested this idea by mixing cells with an increasing amount of T7-ATR_{41–227} in the presence of a constant amount of PA and LF_N-DTA, and then measuring the subsequent effect on protein synthesis (Fig. 4). T7-ATR_{41–227} was an effective inhibitor of toxin action, inhibiting toxin activity by 50% and 100% at concentrations of 80 and 500 nM, respectively. T7-ATR_{41–227} did not, however, inhibit diphtheria toxin (data not shown).

We have identified a 368-amino-acid human protein, ATR, that contains a single extracellular VWA/I domain and serves as the cellular receptor for anthrax toxin. The clone that encodes this

protein may be one of several alternatively spliced messenger RNA transcripts, including TEM8, that result from a primary mRNA. Because TEM8 also contains the extracellular VWA/I domain, which binds directly to PA, we predict that this clone may also function as a PA receptor. The identification of ATR now allows for a more detailed investigation of the mechanism of uptake by cells of anthrax toxin. Furthermore, that the soluble VWA/I domain of ATR inhibits toxin action, coupled with the use of the cloned receptor as a tool for identifying inhibitors of the PA-receptor interaction, holds promise for the development of new approaches for the treatment of anthrax.

Note added in proof: A further apparently full-length ATR/TEM8-related cDNA clone has been reported (GenBank accession code BC012074), which encodes a protein with yet another C-terminal end. □

Methods

Mutagenesis and characterization of CHO-K1 cells

About 5×10^7 CHO-K1 cells were treated at 37 °C for 7 h with medium containing $10 \mu\text{g ml}^{-1}$ ICR-191 (Sigma) then washed twice. After 4 d, surviving cells were replated and incubated for 3 d with medium containing $8 \mu\text{g ml}^{-1}$ PA and 10 ng ml^{-1} LF_N-DTA. Surviving single-cell clones were isolated 14 d later. CHO-R1.1 cells were assayed for their sensitivity to DT intoxication by measuring incorporation of ³H-leucine into cellular proteins after exposure to the toxin¹⁶. Flow cytometry analysis was performed after incubating cells at 4 °C for 2 h in medium containing 40–80 nM OGPA (PA-K563C coupled to Oregon Green maleimide (Molecular Probes)). The cells were then washed twice with medium and analysed with a Becton Dickinson FACSCalibur flow cytometer.

cDNA complementation

About 5×10^5 CHO-R1.1 cells were transduced with $\sim 10^7$ infectious units (complexity of library = 2×10^6 independent clones) of the pLIB-based cDNA library (Clontech) produced in the 293GPG packaging cell line²⁷. Three days later, cells were incubated with medium containing 80 nM OGPA and the top 0.1% of fluorescent cells were then isolated by sorting using a Becton Dickinson FACS Vantage SE instrument. These cells were expanded and subjected to four additional rounds of sorting using OGPA as above, as well as a 1:500 dilution of a rabbit anti-PA polyclonal serum along with a 1:500 dilution of an APC-conjugated secondary antibody (Molecular Probes). OGPA single positive (round 2) or OGPA/APC double positive (rounds 3–5) cells were recovered (the top 20%, 1%, 5% and 50% of fluorescent cells for rounds 2, 3, 4 and 5, respectively) and expanded after each round of sorting. The cDNA inserts contained within these cells were recovered by PCR amplification of genomic DNA samples with oligonucleotide primers specific for the MLV vector according to the manufacturer's instructions (Clontech). Each cDNA was sub-cloned between the *NotI* and *Sall* restriction enzyme sites of pLIB and the resulting plasmids were cotransfected into 293 cells with MLV gag/pol and VSV-G expression plasmids pMD.old.gagpol and pMD.G²⁸. Resulting pseudotyped virus particles were used to infect CHO-R1.1 and CHO-K1 cells followed by OGPA staining and FACS analysis as above. All sequencing was performed by the McArdle Laboratory macromolecular core.

Cloning and expression of T7-ATR_{41–227}

A DNA fragment encoding amino acids 41–227 of ATR was cloned into the *Bam*H1 and *Eco*R1 sites of pET28A (Novagen) to generate pET28A-ATR_{41–227}. BL21 (DE3) cells (Stratagene) containing pET28A-ATR_{41–227} were grown at 37 °C to an absorbance at 600 nm (*A*₆₀₀) of 0.6, induced with 1 mM isopropyl-β-D-thiogalactopyranoside for 4 h and collected by centrifugation. The cells from 1.5 l of culture were resuspended in 25 ml of 50 mM Tris-HCl buffer at pH 8.0, 2 mM dithiothreitol (DTT) and 1 mM phenylmethylsulphonyl fluoride, and were passed through a French press. We added 1 mg of DNase I (Roche) to the cell lysate, which we then sonicated for 1 min and centrifuged at 21,000g for 20 min. The pellet was resuspended in 25 ml of 50 mM Tris-HCl at pH 8.0 and 2 mM DTT, and centrifuged at 21,000g for 20 min. This wash step was repeated once. T7-ATR_{41–227} was solubilized and folded essentially as described previously²⁹.

Isolation of PA-N682S

The DNA encoding domain 4 of PA was mutagenized by error-prone PCR³¹. Clones were expressed in *E. coli*, and lysates derived from these clones were added to CHO-K1 cells in combination with LF_N-DTA. Clones corresponding to lysates that did not kill CHO-K1 cells were sequenced and the N682S mutant clone was further characterized here.

Co-immunoprecipitation of PA and T7-ATR_{41–227}

A mixture of 5 μg PA (wild type or N682S) and 2 μg T7-ATR_{41–227} (in 20 mM Tris-HCl at pH 8.0, 150 mM NaCl and 0.1 mg ml⁻¹ bovine serum albumin) was incubated on ice for 30 min in the presence or absence of 2 mM EDTA. Anti-PA polyclonal serum (10 μl) was added to this solution and incubated on ice for an additional 1 h. Protein A agarose (Santa Cruz Biotechnology) was added and the solution was rotated at 4 °C for 1 h, then washed four times with 20 mM Tris-HCl at pH 8.0 and 150 mM NaCl. About one-third of the mixture was subjected to SDS-PAGE, transferred to nitrocellulose and probed with anti-T7 antibody conjugated to horseradish peroxidase (Novagen).




Figure 4 T7-ATR_{41–227} protects cells from killing by PA with LF_N-DTA. CHO-K1 cells were incubated at 37 °C for 4 h with 10^{-10} M PA, 2.5×10^{-11} M LF_N-DTA and increasing amounts of T7-ATR_{41–227}. Toxin sensitivity was determined by measuring the inhibition of protein synthesis as determined in Fig. 1c.

GST-D4 pull-down assay

DNA encoding amino acids 595–735 of PA (domain 4) was cloned into pGEX-4T-1 (Pharmacia Biotechnology). GST-D4 was coupled to glutathione sepharose at 4 mg ml⁻¹ GST-D4 according to the manufacturer's instructions (Pharmacia Biotechnology). GST or GST-D4 coupled to glutathione sepharose was mixed with 2 µg of T7-ATR₄₁₋₂₂₇ and 250 µg of *E. coli* extract in 250 µl for 1 h at 4 °C. The beads were washed four times with 20 mM Tris-HCl at pH 8.0 and 150 mM NaCl. One-half of the suspension was subjected to SDS-PAGE, transferred to nitrocellulose, and probed with anti-T7 antibody coupled to horseradish peroxidase.

Received 21 September; accepted 10 October 2001.
Published online 23 October 2001, DOI: 10.1038/n35101999

1. Leppla, S. H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cAMP concentrations in eukaryotic cells. *Proc. Natl Acad. Sci. USA* **79**, 3162–3166 (1982).
2. O'Brien, J. *et al.* Effects of anthrax toxin components on human neutrophils. *Infect. Immun.* **47**, 306–310 (1985).
3. Duesbery, N. S. *et al.* Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. *Science* **280**, 734–737 (1998).
4. Pellizzari, R. *et al.* Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFN γ -induced release of NO and TNF α . *FEBS Lett.* **462**, 199–204 (1999).
5. Friedlander, A. M. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. *J. Biol. Chem.* **261**, 7123–7126 (1986).
6. Molloy, S. S. *et al.* Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. *J. Biol. Chem.* **267**, 16396–16402 (1992).
7. Milne, J. C. *et al.* Anthrax protective antigen forms oligomers during intoxication of mammalian cells. *J. Biol. Chem.* **269**, 20607–20612 (1994).
8. Elliott, J. L., Mogridge, J. & Collier, R. J. A quantitative study of the interactions of *Bacillus anthracis* edema factor and lethal factor with activated protective antigen. *Biochemistry* **39**, 6706–6713 (2000).
9. Gordon, V. M., Leppla, S. H. & Hewlitt, E. L. Inhibitors of receptor-mediated endocytosis block the entry of *Bacillus anthracis* adenylate cyclase toxin but not that of *Bordetella pertussis* adenylate cyclase toxin. *Infect. Immun.* **56**, 1066–1069 (1988).
10. Blaustein, R. O., Koehler, T. M., Collier, R. J. & Finkelstein, A. Anthrax toxin: Channel-forming activity of protective antigen in planar phospholipid bilayers. *Proc. Natl Acad. Sci. USA* **86**, 2209–2213 (1989).
11. Koehler, T. M. & Collier, R. J. Anthrax toxin protective antigen: low-pH-induced hydrophobicity and channel formation in liposomes. *Mol. Microbiol.* **5**, 1501–1506 (1991).
12. Milne, J. C. & Collier, R. J. pH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen. *Mol. Microbiol.* **10**, 647–653 (1993).
13. Escuyer, V. & Collier, R. J. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. *Infect. Immun.* **59**, 3381–3386 (1991).
14. Friedlander, A. M. *et al.* Characterization of macrophage sensitivity and resistance to anthrax lethal toxin. *Infect. Immun.* **61**, 245–252 (1993).
15. Taft, S. A., Liber, H. L. & Skopek, T. R. Mutational spectrum of ICR-191 at the *hprt* locus in human lymphoblastoid cells. *Environ. Mol. Mutagen.* **23**, 96–100 (1994).
16. Milne, J. C., Blanke, S. R., Hanna, P. C. & Collier, R. J. Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. *Mol. Microbiol.* **15**, 661–666 (1995).
17. Burns, J. C. *et al.* Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. *Proc. Natl Acad. Sci. USA* **90**, 8033–8037 (1993).
18. Kitamura, T. *et al.* Efficient screening of retroviral cDNA expression libraries. *Proc. Natl Acad. Sci. USA* **92**, 9146–9150 (1995).
19. Whitehead, I., Kirk, H. & Kay, R. Expression cloning of oncogenes by retroviral transfer of cDNA libraries. *Mol. Cell. Biol.* **15**, 704–710 (1995).
20. St Croix, B. *et al.* Genes expressed in human tumor endothelium. *Science* **289**, 1197–1202 (2000).
21. Dickeson, S. K. & Santaro, S. A. Ligand recognition by the I domain-containing integrins. *Cell Mol. Life Sci.* **54**, 556–566 (1998).
22. Lee, J. O., Rieu, P., Arnaout, M. A. & Liddington, R. Crystal structure of the a domain from the subunit of integrin CR3 (CD11b/CD18). *Cell* **80**, 631–638 (1995).
23. Molloy, S. S., Anderson, E. D., Jean, F. & Thomas, G. Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. *Trends Cell Biol.* **9**, 28–35 (1999).
24. Beauregard, K. E., Wimer-Mackin, S., Collier, R. J. & Lencer, W. I. Anthrax toxin entry into polarized epithelial cells. *Infect. Immun.* **67**, 3026–3030 (1999).
25. Petosa, C. *et al.* Crystal structure of the anthrax toxin protective antigen. *Nature* **385**, 833–838 (1997).
26. Varughese, M., Teixeira, A. V., Liu, S. & Leppla, S. H. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. *Infect. Immun.* **67**, 1860–1865 (1999).
27. Ory, D. S., Neugeboren, B. A. & Mulligan, R. C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. *Proc. Natl Acad. Sci. USA* **93**, 11400–11406 (1996).
28. Snitkovsky, S. *et al.* A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor. *J. Virol.* **74**, 9540–9545 (2000).
29. Legge, G. B. *et al.* NMR solution structure of the inserted domain of human leukocyte function associated antigen-1. *J. Mol. Biol.* **295**, 1251–1264 (2000).
30. Emsley, J., King, S. L., Bergelson, J. M. & Liddington, R. C. Crystal structure of the I domain from Integrin $\alpha 2\beta 1$. *J. Biol. Chem.* **272**, 28512–28517 (1997).
31. Mogridge, J., Mourez, M. & Collier, R. J. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. *J. Bacteriol.* **183**, 2111–2116 (2001).

Acknowledgements

We thank K. Schell and members of the flow cytometry facility at the University of Wisconsin Comprehensive Cancer Center for performing the cell sorting. This work was

supported by a grant to J.A.T.Y. and R.J.C. from the National Institutes of Health. J.M. was supported in part by a Medical Research Council (Canada) postdoctoral fellowship.

Competing interests statement

The authors declare competing financial interests: details accompany the paper on Nature's website (<http://www.nature.com>).

Correspondence and requests for materials should be addressed to J.A.T.Y. (e-mail: young@oncology.wisc.edu). The ATR cDNA clone has been deposited in GenBank (accession code AF421380).

Crystal structure of the anthrax lethal factor

Andrew D. Pannifer*†, Thiang Yian Wong‡, Robert Schwarzenbacher‡, Martin Renatus‡, Carlo Petosa*†, Jadwiga Bienkowska†§, D. Borden Lacy||, R. John Collier||, Sukjoon Park¶, Stephen H. Leppla¶, Philip Hanna# & Robert C. Liddington‡

* *Biochemistry Department, University of Leicester, Leicester LE1 7RH, UK*

‡ *The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA*

§ *Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA*

|| *Department of Microbiology and Molecular Genetics, Harvard Medical School, 200 Longwood Avenue, Boston, Massachusetts 02115, USA*

¶ *National Institute of Dental and Craniofacial Research, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA*

Department of Microbiology and Immunology, University of Michigan Medical School, 5641 Medical Science II, Ann Arbor, Michigan 48109, USA

Lethal factor (LF) is a protein (relative molecular mass 90,000) that is critical in the pathogenesis of anthrax^{1–3}. It is a highly specific protease that cleaves members of the mitogen-activated protein kinase kinase (MAPKK) family near to their amino termini, leading to the inhibition of one or more signalling pathways^{4–6}. Here we describe the crystal structure of LF and its complex with the N terminus of MAPKK-2. LF comprises four domains: domain I binds the membrane-translocating component of anthrax toxin, the protective antigen (PA); domains II, III and IV together create a long deep groove that holds the 16-residue N-terminal tail of MAPKK-2 before cleavage. Domain II resembles the ADP-ribosylating toxin from *Bacillus cereus*, but the active site has been mutated and recruited to augment substrate recognition. Domain III is inserted into domain II, and seems to have arisen from a repeated duplication of a structural element of domain II. Domain IV is distantly related to the zinc metalloprotease family, and contains the catalytic centre; it also resembles domain I. The structure thus reveals a protein that has evolved through a process of gene duplication, mutation and fusion, into an enzyme with high and unusual specificity.

Anthrax poses a significant threat as an agent of biological warfare and terrorism⁷. Inhalational anthrax, in which spores of *Bacillus anthracis* are inhaled, is almost always fatal, as diagnosis is rarely possible before the disease has progressed to a point where antibiotic treatment is ineffective. The major virulence factors of *B. anthracis* are a poly-D-glutamic acid capsule and anthrax toxin¹. Anthrax toxin consists of three distinct proteins that act in concert: two enzymes, LF and oedema factor (an adenylate

† Present addresses: AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK (A.P.); EMBL Grenoble Outstation, 38042 Grenoble Cedex 9, France (C.P.); Boston University, 36 Cummington Street, Boston, Massachusetts 02215, USA (J.B.).